CAR T-cell therapy, first approved by the FDA in 2017, involves the isolation and activation of T cells from a patient’s blood for ex vivo genetic modification, with CRISPR-Cas9 being a widely used nonviral editing tool for this application. The Cas9 nuclease plays a significant role in the performance of the tool and is thus a critical component for therapy development.
This application note from Thermo Fisher Scientific discusses the performance of GMP-manufactured Cas9 nucleases for cell therapy applications, specifically in the context of Chimeric antigen receptor (CAR) T-cell therapy, and introduces the Gibco CTS TrueCut Cas9 Protein.
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific